Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Digestive Diseases and Sciences Année : 2021

Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France

Denis Ouzan
Dominique Larrey
Andre-Jean Remy
  • Fonction : Auteur
  • PersonId : 1099021
Ghassan Riachi
  • Fonction : Auteur
  • PersonId : 1099022
Regine Truchi
  • Fonction : Auteur
  • PersonId : 1099024
Jean-Marc Combis
  • Fonction : Auteur
  • PersonId : 906173
Francois Bailly
  • Fonction : Auteur
  • PersonId : 955477
Isabelle Rosa
  • Fonction : Auteur
  • PersonId : 1099025
Christophe Hezode
  • Fonction : Auteur
  • PersonId : 1099026
Denise Glorian-Petraud
  • Fonction : Auteur
  • PersonId : 1099027
Olivier Libert
  • Fonction : Auteur
  • PersonId : 1099028
Heribert Ramroth
  • Fonction : Auteur
  • PersonId : 1099029
Gerard Thiefin
  • Fonction : Auteur
  • PersonId : 1099030
Dominique Roulot
  • Fonction : Auteur
  • PersonId : 853994
Bruno Roche
  • Fonction : Auteur
  • PersonId : 881472
Vincent Leroy
  • Fonction : Auteur
  • PersonId : 1099031
Jérôme Dumortier
Dominique Thabut
  • Fonction : Auteur
  • PersonId : 1099032
Stanislas Pol

Résumé

Background Treatment of hepatitis C virus (HCV) has been dramatically improved with the introduction of direct-acting antiviral agents (DAAs). Universal access to pangenotypic DAAs was provided in France from 2017, expanding the type of patients treated. Real-world studies are important to confirm effectiveness and safety in clinical practice, particularly in vulnerable populations. Aims To assess real-world effectiveness and safety of sofosbuvir-based therapy in adults with chronic HCV infection before and after universal access to DAAs in France. Methods This multicenter, non-interventional, prospective study assessed the effectiveness, safety, patient-reported outcomes and adherence with sofosbuvir-based regimens from October 2015 to July 2016 (Period 1: sofosbuvir-based therapy excluding sofosbuvir/velpatasvir) and from October 2017 to July 2018 (Period 2: pangenotypic sofosbuvir/velpatasvir-based therapy). Results Baseline data were documented for 1029 patients. Overall, 797 (77%) had sustained virologic response data available >= 9 weeks after treatment completion. Per protocol response was high (97%) irrespective of age, alcohol consumption, recreational drug use, or HIV/HCV coinfection. Adverse events occurred in approximately 25% of patients with the majority experiencing Grade 1 or 2 events. Sofosbuvir-based regimens improved health-related quality of life from baseline to end of treatment in patients with data at all timepoints. Overall, 99% of patients reported total or almost total adherence to therapy. Conclusions Sofosbuvir-based therapy, including pangenotypic sofosbuvir/velpatasvir, is effective for the treatment of HCV in real-world clinical practice. This is an important step towards HCV elimination.
Fichier non déposé

Dates et versions

hal-03228797 , version 1 (18-05-2021)

Identifiants

Citer

Denis Ouzan, Dominique Larrey, Dominique Guyader, Andre-Jean Remy, Ghassan Riachi, et al.. Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France. Digestive Diseases and Sciences, 2021, 66 (3), pp.881-898. ⟨10.1007/s10620-020-06234-1⟩. ⟨hal-03228797⟩
36 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More